FibroBiologics, Charles River Laboratories Team Up to Make Fibroblast-Based Treatments for Chronic Diseases

MT Newswires Live

2024/10/18

FibroBiologics (FBLG) and Charles River Laboratories (CRL) said Friday they have set up a master services agreement to make FibroBiologics' fibroblast-based CYWC628 for a diabetic foot ulcer trial expected to start next year.

FibroBiologics is assessing the potential treatment of chronic diseases using fibroblasts, the companies said, adding indications being evaluated include: wound healing, multiple sclerosis, degenerative disc disease, psoriasis, thymic involution reversal, as well as cancer.

Charles River will be the contract development and manufacturing organization that will make the drug products for FibroBiologics' upcoming study, the companies said.

Financial details weren't provided.

Price: 3.4500, Change: +0.13, Percent Change: +3.92

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2476237627"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2476237627\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2476237627?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-18 21:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2476237627","market":"nz","top_or_hot":-1,"title":"FibroBiologics, Charles River Laboratories Team Up to Make Fibroblast-Based Treatments for Chronic Diseases","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/FBLG\">FibroBiologics</a> (FBLG) and Charles River Laboratories (CRL) said Friday they have set up a master services agreement to make FibroBiologics' fibroblast-based CYWC628 for a diabetic foot ulcer trial expected to start next year.</p><p>FibroBiologics is assessing the potential treatment of chronic diseases using fibroblasts, the companies said, adding indications being evaluated include: wound healing, multiple sclerosis, degenerative disc disease, psoriasis, thymic involution reversal, as well as cancer.</p><p>Charles River will be the contract development and manufacturing organization that will make the drug products for FibroBiologics' upcoming study, the companies said.</p><p>Financial details weren't provided.</p><p>Price: 3.4500, Change: +0.13, Percent Change: +3.92</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FibroBiologics, Charles River Laboratories Team Up to Make Fibroblast-Based Treatments for Chronic Diseases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFibroBiologics, Charles River Laboratories Team Up to Make Fibroblast-Based Treatments for Chronic Diseases\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-10-18 21:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/FBLG\">FibroBiologics</a> (FBLG) and Charles River Laboratories (CRL) said Friday they have set up a master services agreement to make FibroBiologics' fibroblast-based CYWC628 for a diabetic foot ulcer trial expected to start next year.</p><p>FibroBiologics is assessing the potential treatment of chronic diseases using fibroblasts, the companies said, adding indications being evaluated include: wound healing, multiple sclerosis, degenerative disc disease, psoriasis, thymic involution reversal, as well as cancer.</p><p>Charles River will be the contract development and manufacturing organization that will make the drug products for FibroBiologics' upcoming study, the companies said.</p><p>Financial details weren't provided.</p><p>Price: 3.4500, Change: +0.13, Percent Change: +3.92</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7095","symbol_name":"多种金属与采矿","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2476237627","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2476237627","pubTimestamp":1729257931,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"FibroBiologics (FBLG) and Charles River Laboratories (CRL) said Friday they have set up a master services agreement to make FibroBiologics' fibroblast-based CYWC628 for a diabetic foot ulcer trial exp","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7095":"多种金属与采矿","BK4120":"环境与设施服务","TISI":"Team Inc","BK4588":"碎股","LU0390134368.USD":"FRANKLIN GLOBAL GROWTH \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","BK4530":"医药外包概念","CRL.AU":"Comet Resources Ltd","CRL":"查尔斯河","BK4139":"生物科技","BK4121":"生命科学工具和服务","FBLG":"FibroBiologics"},"translate_title":"FibroBiologics与Charles River Laboratories合作开发基于成纤维细胞的慢性病治疗方法","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRL":1,"CRL.AU":1,"FBLG":1,"TISI":1},"content_text":"FibroBiologics (FBLG) and Charles River Laboratories (CRL) said Friday they have set up a master services agreement to make FibroBiologics' fibroblast-based CYWC628 for a diabetic foot ulcer trial expected to start next year.FibroBiologics is assessing the potential treatment of chronic diseases using fibroblasts, the companies said, adding indications being evaluated include: wound healing, multiple sclerosis, degenerative disc disease, psoriasis, thymic involution reversal, as well as cancer.Charles River will be the contract development and manufacturing organization that will make the drug products for FibroBiologics' upcoming study, the companies said.Financial details weren't provided.Price: 3.4500, Change: +0.13, Percent Change: +3.92","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}